从价值医疗视角探讨EGFR突变阳性晚期非小细胞肺癌一线EGFR-TKI的选择  

Choice of First-line EGFR-TKI Therapy for EGFR-mutated Advanced Non-small Cell Lung Cancer from the Perspective of Value Medical Treatment

作　　者：杨雯靖 史琳[1] 陈芋屹 周杰[1] 刘梓燊 张兴涵 杨国旺[1] YANG Wen-jin;SHI Lin;CHEN Yu-yi;ZHOU Jie;LIU Zi-shen;ZHANG Xing-han;YANG Guo-wang(Beijing Hospital of Traditiondl Chinese Medicine,Capital Medical University,Beijing 100010,China)

机构地区：[1]首都医科大学附属北京中医医院,北京100010

出　　处：《肿瘤学杂志》2022年第10期802-808,共7页Journal of Chinese Oncology

基　　金：国家重点研发计划(2018YFC1705101)。

摘　　要：肺癌的发病率和死亡率均居我国恶性肿瘤的首位,且以晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者占比最高。众多表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)被推荐用于表皮生长因子受体(epidermal growth factor receptor,EGFR)突变阳性晚期NSCLC的一线治疗,但指导个体化临床实践仍面临挑战。目前价值医疗相关的研究及实践正盛,全文尝试从价值医疗视角(有效性、安全性、可及性)探讨EGFR突变阳性晚期NSCLC个体化一线EGFR-TKI的选择,以期为指南指导下EGFR-TKI个体化应用及践行价值医疗服务提供参考。Both the incidence and mortality of lung cancer rank first among malignant tumors in China, and the proportion of advanced non-small cell lung cancer(NSCLC) is the highest. The epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) are recommended for the first-line treatment of advanced NSCLC with EGFR mutations, but there are still challenges in guiding individualized clinical practice. At present, research and practice related to value medicine are flourishing. This article aims to explore the selection of the appropriate EGFR-TKIs for the first-line personalized treatment in advanced NSCLC with EGFR mutations from the perspective of value medicine in terms of effectiveness, safety, and accessibility;and also provides reference for the individualized application of EGFR-TKIs and the practice of valuable medical services under clinical guidelines.

关 键 词：表皮生长因子受体突变 表皮生长因子受体酪氨酸激酶抑制剂 非小细胞肺癌 价值医疗 

分 类 号：R734.2[医药卫生—肿瘤]